CPGS

MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder

In an exploratory analysis of 32 participants from a Phase 2 open‑label trial of manualised MDMA‑assisted therapy for PTSD, 84% reported chronic pain and 75% reported pain‑related disability. MDMA‑AT was associated with significant reductions in pain intensity, disability and overall Chronic Pain Grade Scale severity in the high‑pain subgroup and reduced pain intensity in the medium‑pain subgroup, supporting further investigation of MDMA‑AT for comorbid chronic pain.

Published

November 3, 2022

Journal

Frontiers in Psychiatry

Authors

Christie, D., Yazar-Klosinski, B., Nosova, E., Kryskow, P., Siu, W. O., Lessor, D., Argento, E.